Get the Stockscreener App
2.245
1.21%
-0.035
Black Diamond Therapeutics Inc stock is traded at $2.245, with a volume of 91,393.
It is down -1.21% in the last 24 hours and up +0.55% over the past month.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.28
Open:
$2.32
24h Volume:
91,393
Relative Volume:
0.12
Market Cap:
$129.01M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.1941
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
-4.97%
1M Performance:
+0.55%
6M Performance:
-65.51%
1Y Performance:
-51.77%
1-Day Range:
$2.245
$2.33
1-Week Range:
$2.24
$2.47
52-Week Range:
$1.91
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.245 | 129.01M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.12 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.85 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.81 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.16 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.76 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Update - MarketBeat
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Significant Decline in Short Interest - Defense World
NAYA Biosciences Announces Nomination of New Board Members - The Manila Times
February 2025 US Penny Stocks With Promising Prospects - Simply Wall St
SG Americas Securities LLC Makes New $42,000 Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: A Year of Market Fluctuations - The InvestChronicle
PL’s Stock Market Adventure: 60.64% YTD Growth Amidst Volatility - The InvestChronicle
Cemex S.A.B. De C.V. ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Black Diamond Therapeutics Inc (BDTX) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Axcelis Technologies Inc (ACLS) Shares Down Despite Recent Market Volatility - The News Heater
Analyzing the Price-to-Earnings Ratio of Black Diamond Therapeutics Inc (BDTX) - The News Heater
Molina Healthcare Inc’s Banking’s 100-Day Moving Average at 311.64: Will the Stock Break Through? - The InvestChronicle
Analyzing the Price-to-Earnings Ratio of Smithfield Foods, Inc (SFD) - The News Heater
CPAY Stock Sees Surge of Approximately 1.95% in Last Five Days - Knox Daily
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.25 - Knox Daily
CVRx Inc [CVRX] Shares Fall -7.20 % on Wednesday - Knox Daily
Post Holdings Inc [POST] Shares Jump Approximately 3.76% Over the Year - Knox Daily
How to interpret Black Diamond Therapeutics Inc (BDTX)’s stock chart patterns - US Post News
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Significant Growth in Short Interest - MarketBeat
Trading Day Triumph: Fractyl Health Inc (GUTS) Ends at 1.70, a -7.61 Surge/Plunge - The Dwinnex
Investor’s Delight: Relmada Therapeutics Inc (RLMD) Closes Weak at 0.34, Down -2.61 - The Dwinnex
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Barclays PLC Has $339,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
3 US Penny Stocks With Market Caps Under $200M - Simply Wall St
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance
BDTX stock touches 52-week low at $2.08 amid market challenges - Investing.com
Roche purchases shares in tender offer for Poseida Therapeutics, Inc. - Yahoo Finance
Soleno Therapeutics, Inc. (NASDAQ:SLNO): When Will It Breakeven? - Yahoo Finance
XORTX Adds Late Stage Gout Program to Pipeline - Yahoo Finance
Geode Capital Management LLC Raises Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Geode Capital Management LLC Grows Stock Holdings in BARK, Inc. (NYSE:BARK) - Defense World
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Geode Capital Management LLC Buys 50,579 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Barclays PLC Has $339,000 Stock Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Why Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now? - Yahoo Finance
State Street Corp Buys 118,764 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts (BDTX) - Seeking Alpha
Barclays PLC Has $1.10 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Will TG Therapeutics, Inc. (TGTX) Make You Rich In 2025? - Yahoo Finance
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Yahoo Finance
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week - Yahoo Finance
Charles Schwab Investment Management Inc. Boosts Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $2.31 amid market challenges - Investing.com India
Analytical Overview: Black Diamond Therapeutics Inc (BDTX)’s Ratios Tell a Financial Story - The Dwinnex
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):